Simone STEINER

Simone Steiner serves as Chief of Technical Officer since 2025. Dr. Simone Steiner, PhD is a Senior Executive and Board Advisor with almost 20 years of pharma experience across preclinical, clinical and commercialization gained within organizations ranging from startups to multinational Pharma companies. Prior to joining Transgene, she was the Chief Technical Operating Officer (CTOO)… Continue reading Simone STEINER

Maurizio CEPPI, PhD

Maurizio Ceppi, PhD, has served as Chief Scientific Officer (Vice President in charge of Research and Development ) since 2024. He brings over 15 years in the oncology life sciences industry, he holds a deep expertise in cancer immunotherapy and precision medicine. Throughout his career, Maurizio Ceppi has played a pivotal role in the preclinical… Continue reading Maurizio CEPPI, PhD

Emmanuelle DOCHY, MD

Emmanuelle Dochy, MD, joined Transgene in September 2024 as Chief Medical Officer (CMO). Emmanuelle Dochy, MD, has served Transgene as Chief Medical Officer (VP Medical and Regulatory Affairs) since 2024. Emmanuelle Dochy was previously Vice President of Global Medical Affairs at Bayer, where she gained extensive experience in managing medical affairs on a global scale.… Continue reading Emmanuelle DOCHY, MD

doublon Lucie Larguier

Lucie is appointed on March 27 as Chief Financial Officer, responsible for all aspects of the Company’s financial strategy, management and operations to ensure efficient delivery of Transgene’s innovative immunotherapy pipeline. Since 2016, Lucie has served as Director Corporate Communications and Investor Relations, reporting to the CEO and joins the Executive Comity in October 2023… Continue reading doublon Lucie Larguier

Michel Baguenault

Michel Baguenault de Puchesse has been CEO of Institut Mérieux since January 2020. Prior to this position, Michel held several positions within the Institut Mérieux group: Executive Vice President of Institut Mérieux (2009 – 2011), Corporate Vice President, HR and Communication of bioMérieux (2011 – 2016), Secretary General of bioMérieux, in charge of Human Resources,… Continue reading Michel Baguenault

Pedro Romero, MD

Pedro Romero, MD, is Professor at the Faculty of Biology and Medicine, University of Lausanne, where he has worked since 2003, focusing on tumor immunology and cancer immunotherapy, particularly on the biology and dynamics of cytolytic CD8 T lymphocyte (CTL) responses. He is also Editor-in-Chief of the Journal for ImmunoTherapy of Cancer. Previously, Pedro researched at… Continue reading Pedro Romero, MD

John C. Bell, PhD

John C. Bell, PhD, is an internationally renowned expert in using oncolytic viruses (OVs) to treat cancer. He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics. He is the Scientific Director of BioCanRx, a Network of Centers of Excellence developing and clinically testing novel immunotherapeutics… Continue reading John C. Bell, PhD

Carol Stuckley

Carol Stuckley brings more than 35 years of experience as a strategic and international financial executive, with proven success leading finance teams and creating shareholder value for healthcare companies. She currently serves as a Board Director and Chairperson of the audit committee of Centessa Pharmaceuticals, plc and previously served on the board of directors of… Continue reading Carol Stuckley

Prof. Jean-Yves Blay

Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Léon Bérard Center in Lyon since 2014. He holds a PhD obtained in 1994 from the Claude Bernard University in Lyon and has been authorized to supervise research since 1996. He currently leads the LYriCAN project (integrated cancer research) at the… Continue reading Prof. Jean-Yves Blay

Dr. Alessandro Riva

Alessandro Riva joined Transgene in 2022 as Chairman of the Board of Directors and became Chief Executive Officer in 2023. He brings nearly 30 years’ experience in the Life Sciences industry, in pharmaceutical and biotech companies. He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and CEO of Ichnos Sciences.… Continue reading Dr. Alessandro Riva